Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -172.34% is 98% above its 3-year average of -6948.26%, around the middle of its 3-year range (-35778.79%–29288.14%).
96.44% above its 12-month average of -4834.32%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -61.35%.
EBITDA MARGIN
-172.34%
EBITDA MARGIN AVG TTM
-4834.32%
EBITDA MARGIN AVG 3Y
-6948.26%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+96.44%
CURRENT VS 3Y AVG
+97.52%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Septerna Inc
Market Cap
$1.61B
EBITDA Margin
-172.34%
TTM Avg
-4834.32%
3Y Avg
-6948.26%
5Y Avg
N/A
Market Cap
$1.61B
EBITDA Margin
-512.70%
TTM Avg
-388.17%
3Y Avg
-265.21%
5Y Avg
-263.30%
Market Cap
$1.60B
EBITDA Margin
-1075.09%
TTM Avg
-854.02%
3Y Avg
-886.21%
5Y Avg
-631.69%
Market Cap
$1.62B
EBITDA Margin
0.06%
TTM Avg
-4.29%
3Y Avg
-15.38%
5Y Avg
-22.40%
Market Cap
$1.63B
EBITDA Margin
19.54%
TTM Avg
15.33%
3Y Avg
15.07%
5Y Avg
12.91%
Market Cap
$1.59B
EBITDA Margin
-164.52%
TTM Avg
-214.39%
3Y Avg
-473.06%
5Y Avg
-473.06%
Market Cap
$1.57B
EBITDA Margin
-10.20%
TTM Avg
-140.78%
3Y Avg
-597.36%
5Y Avg
-597.36%
Market Cap
$1.54B
EBITDA Margin
-158.44%
TTM Avg
-796.42%
3Y Avg
-796.42%
5Y Avg
-1562.06%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Septerna Inc (SEPN) | $1.61B | -172.34% | -4834.32% | -6948.26% | N/A |
| Ocular Therapeutix, Inc. (OCUL)vs › | $1.61B | -512.70% | -388.17% | -265.21% | -263.30% |
| Omnicell, Inc. (OMCL)vs › | $1.61B | 8.30% | 8.20% | 7.63% | 9.66% |
| uniQure N.V. (QURE)vs › | $1.60B | -1075.09% | -854.02% | -886.21% | -631.69% |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.62B | 0.06% | -4.29% | -15.38% | -22.40% |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.63B | 19.54% | 15.33% | 15.07% | 12.91% |
| Kestra Medical Technologies, Ltd. (KMTS)vs › | $1.59B | -164.52% | -214.39% | -473.06% | -473.06% |
| Stoke Therapeutics, Inc. (STOK)vs › | $1.57B | -10.20% | -140.78% | -597.36% | -597.36% |
| Syndax Pharmaceuticals, Inc. (SNDX)vs › | $1.54B | -158.44% | -796.42% | -796.42% | -1562.06% |
| Innoviva, Inc. (INVA)vs › | $1.54B | 47.98% | 50.86% | 52.39% | 67.36% |
Gross Margin
99.6%
EBITDA Margin
-172.3%
Operating Margin
-175.8%
Net Margin
-24.5%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -61.35% |
| 2026-03-31 | -48.56% |
| 2025-12-31 | -64.77% |
| 2025-09-30 | 14.03% |
| 2025-06-30 | -24010.92% |
| 2025-03-31 | -11649.77% |
| 2024-12-31 | -11476.42% |
| 2024-09-30 | -12605.68% |
| 2024-06-30 | -4792.43% |
| 2024-03-31 | -4786.75% |
| 2023-12-31 | 29288.14% |
| 2023-09-30 | -35778.79% |
